Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 10/20 | 0.68 |
| ▸ | CDK2 | P24941 | 12/20 | 0.67 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.67 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.67 |
| ▸ | CDK1 | P06493 | 5/20 | 0.60 |
| ▸ | SRC | P12931 | 3/20 | 0.58 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.56 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.56 |
| ▸ | CDK4 | P11802 | 3/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.56 |
| ▸ | CCND1 | P24385 | 3/20 | 0.56 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4381865 | 1.00 | FLT3 (0.68) | FLT3CDK2PDGFRACCNE1CDK1 | |
| SCHEMBL4371963 | 0.92 | FLT3 (0.61) | FLT3CDK2PDGFRACCNE1CDK1 | |
| SCHEMBL4372064 | 0.92 | FLT3 (0.68) | FLT3CDK2PDGFRACCNE1CDK1 | |
| SCHEMBL4373084 | 0.92 | CDK2 (0.64) | FLT3CDK2PDGFRACCNE1CDK1 | |
| SCHEMBL4375250 | 0.92 | CDK2 (0.64) | FLT3CDK2PDGFRACCNE1CDK1 | |
| SCHEMBL4372817 | 0.92 | FLT3 (0.68) | FLT3CDK2PDGFRACCNE1CDK1 | |
| SCHEMBL4375253 | 0.92 | CDK2 (0.64) | FLT3CDK2PDGFRACCNE1CDK1 | |
| SCHEMBL4371960 | 0.92 | FLT3 (0.61) | FLT3CDK2PDGFRACCNE1CDK1 | |
| SCHEMBL4372831 | 0.92 | CDK2 (0.64) | FLT3CDK2PDGFRACCNE1CDK1 | |
| SCHEMBL4374602 | 0.92 | CDK2 (0.64) | FLT3CDK2PDGFRACCNE1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377579-B1 | ACYL AND SULFONYL DERIVATIVES OF 6,9-DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | AVENTIS PHARMA INC (US) | 2009-03-25 | — | — | EP | claimed |
| US-6861524-B2 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-01 | — | — | US | claimed |
| EP-1377579-A2 | ACYL AND SULFONYL DERIVATIVES OF 6,9-DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | Aventis Pharmaceuticals Inc. (US) | 2004-01-07 | — | — | EP | claimed |
| US-20030069259-A1 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | AVENTISUB LLC | 2003-04-10 | — | — | US | claimed |
| WO-2002042303-A2 | ACYL AND SULFONYL DERIVATIVES OF 6,9-DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-05-30 | — | — | WO | claimed |
| EP-1377579-B1 | ACYL AND SULFONYL DERIVATIVES OF 6,9-DISUBSTITUTED 2-(TRANS-1,4-DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | AVENTIS PHARMA INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7429595-B2 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | AVENTIS PHARMACEUTICALS INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-6861524-B2 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069259-A1 | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents | BAD, BAX, MCL1 | FLT3 1260/4885CDK2 167/4885PDGFRA 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.